Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Discontinued Operations: 2019-2021

Historic Cash from Discontinued Operations for Cumberland Pharmaceuticals (CPIX) over the last 3 years, with Dec 2021 value amounting to $503,318.

  • Cumberland Pharmaceuticals' Cash from Discontinued Operations fell 62.78% to $503,318 in Q4 2021 from the same period last year, while for Dec 2021 it was $2.0 million, marking a year-over-year decrease of 43.31%. This contributed to the annual value of $2.0 million for FY2021, which is 43.31% down from last year.
  • According to the latest figures from Q4 2021, Cumberland Pharmaceuticals' Cash from Discontinued Operations is $503,318, which was up 1.31% from $496,787 recorded in Q3 2021.
  • In the past 5 years, Cumberland Pharmaceuticals' Cash from Discontinued Operations ranged from a high of $3.0 million in Q4 2019 and a low of $38,567 during Q2 2020.
  • In the last 3 years, Cumberland Pharmaceuticals' Cash from Discontinued Operations had a median value of $648,984 in 2020 and averaged $918,680.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Cash from Discontinued Operations tumbled by 97.11% in 2020 and then surged by 1,193.35% in 2021.
  • Over the past 3 years, Cumberland Pharmaceuticals' Cash from Discontinued Operations (Quarterly) stood at $3.0 million in 2019, then tumbled by 55.34% to $1.4 million in 2020, then plummeted by 62.78% to $503,318 in 2021.
  • Its Cash from Discontinued Operations was $503,318 in Q4 2021, compared to $496,787 in Q3 2021 and $498,807 in Q2 2021.